MPR BIO - Your Global CDMO Partner
MPR BIO is a regionally grounded, globally integrated platform that functions as a single, high-performance powerhouse for biopharmaceutical advancement. By integrating proprietary technologies and innovative powdered delivery systems with a comprehensive regulatory, manufacturing, and commercialization infrastructure, we offer a streamlined, end-to-end bridge from initial concept to global market.
Unlike traditional models, MPR BIO eliminates industry fragmentation by aligning innovation, execution, and market access under a single operational and governance framework.
Our Integrated Approach
Accelerate Translation
Rapidly move advanced biopharmaceutical products and services from the lab through to full-scale commercialization.
Exosome Strategy
While exosome-based solutions serve as a primary strategic innovation pillar, MPR BIO operates as a full-service CDMO and commercialization platform
Multi-Modality Support
MPR BIO supports cosmetic, therapeutic, and biologic programs across a diverse range of modalities
Market Focus & Scalability
MPR BIO targets high-demand cosmetics for immediate value while scaling clinically driven therapeutics. Regional manufacturing and clear commercial roadmaps position MPR BIO as local industry leaders.
Partner Roles & Operating Model
.png)
Primary execution, CDMO coordination, and commercialization engine
-
Regulatory strategy & clinical development oversight
-
Global CDMO orchestration
-
Market access & commercialization
Scientific leadership &
manufacturing expertise
-
Proprietary exosome technologies
-
CDMO services & formulation know-how
-
Process development & manufacturing leadership
Technology innovation &
CDMO capabilities
-
Proprietary powdered insulin innovation
-
Advanced CDMO capabilities
-
Operational & technical execution support
End-to-End CDMO Services
MPR BIO operates as an end-to-end execution platform, spanning product development, clinical validation, manufacturing, and regional commercialization.
Rather than functioning as a traditional licensing arrangement, MPR BIO is structured to actively build, validate, and scale products through a shared execution model.
Our integrated approach covers all critical areas of biopharmaceutical development.
Large Molecule R&D and CRO Services
✓ Antibody drug discovery and screening
✓ Antibody engineering and humanization
✓ Protein therapeutic drugability analysis
✓ Pharmacodynamic evaluation and efficacy studies
Comprehensive antibody and protein therapeutic development
Cell Line Development
✓ Construction and process optimization of microbial, yeast, CHO cells, and viruses
✓ Fully commercialized licensed cell lines (CHO-K1, CHOS, HEK 293)
✓ Process scale-up to 50L in development
✓ Rapid CHO cell screening platform achieving 11 g/L expression within 2.5 months
Advanced cell line construction and optimization
✓ Mature cell culture, microbial fermentation, and yeast fermentation platforms
✓ Rapid process lockdown from 3L to 50L
✓ Process optimization and characterization
✓ Maximized product yield, quality, reliability, and scalability
Industry-leading cell culture and fermentation platforms
Upstream Process Development
Formulation & Fill-Finish
✓ Formulation development for proteins, ADCs, and exosomes
✓ Multiple dosage forms (lyophilized, injectable)
✓ Protein concentrations from 3 μg/mL to 200 mg/mL
✓ Packaging compatibility and clinical compatibility studies
Complete formulation development and manufacturing
GMP Cell Therapy Preparation
✓ CAR-T, UCAR-T, CAR-NK, TCR-T cell therapy CDMO services
✓ Automated and closed culture approach for reliable production
✓ Process development, optimization, and validation
✓ IND filling support and stability studies
Advanced cGMP facilities for cell therapy production
✓ Establishment of quality standards and specifications
✓ Analytical method development and validation (EP, ICH Q2(R2) compliant)
✓ Impurity profiling and characterization of biologics
✓ Bioactivity assays, biosafety testing, and stability studies
Comprehensive analytical and quality research services
Analytical Testing Center
✓ Monoclonal antibodies, bispecific antibodies, nanobodies, and fusion proteins
✓ Laboratory-scale purification from micrograms to hundreds of grams
✓ Multiple chromatography processes (AC, AEX, CEX, HIC, multi-mode)
✓ Overall yields exceeding 80% with robust, sustainable processes
Extensive protein purification and separation expertise
Downstream Process & Purification
World-Class Production Capabilities
Bioreactor Portfolio
• 6000L Single-Use Bioreactor (2 Lines)
• 2000L Single-Use Bioreactor (2 Lines)
• 1000L Single-Use Bioreactor (1 Line)
• 500L & 200L Fed-Batch & Perfusion Lines
Media Production
• Non-GMP: 1-50 kg batches
• GMP: 500 kg/batch, 350+ tons annually
• Liquid Media: 500-2000L batches, 480,000+ L annually
• Customized formulations with proprietary IP
Why Choose MPR BIO
Single-Use Technology
All leading global brands (Cytiva, Sartorius, ABEC) with reduced contamination risk and faster turnaround times.
Integrated Platform
Unified governance and execution across development, manufacturing, and commercialization for seamless scaling.
Regulatory Excellence
GMP-compliant facilities and processes supporting IND, BLA, and global regulatory submissions.
Exosome Strategy
Creating an integrated exosome platform designed to move from development → validation → market launch in a controlled, compliant, and scalable way.
The Problem We Solve
Today, exosome programs are often fragmented across:
-
Multiple vendors
-
Inconsistent quality systems
-
Unclear regulatory positioning
-
Disconnected commercialization
Our Solution
MPR BIO replaces fragmentation with one unified operating model:
✓ World-class production readiness
✓ Disciplined regulatory alignment
✓ Clinical validation capabilities
✓ Market access & distributor execution
Strategic Outcome
MPR BIO becomes the trusted exosome partner for professional markets through quality, consistency, and compliant market entry.
Multi-Format Exosome Portfolio
Platform Standard
MSC-derived extracellular vesicles (30–150 nm) in lyophilized format with sterile solvent, utilizing GMP manufacturing model with batch QC consistency and scalable supply.
EV-LUNG-01
Pulmonary Delivery
Inhalation / Nebulized
Advanced respiratory delivery system for therapeutic exosomes
EV-NASAL-01
Nasal Delivery
Nasal Nebulization
Optimized nasal formulation
for systemic and local effects
EV-JOINT-01
Joint Therapy
Intra-articular
Targeted delivery for bone and joint regeneration
EV-EYE-01
Ocular Therapy
Ocular Surface
Specialized formulation
for ophthalmic applications
EV-SKIN-01
Skin Therapy
Topical / Microneedle
Advanced transdermal delivery system
EV-HAIR-01
Hair Growth
Scalp Administration
Targeted therapy for hair growth and scalp health
Registration-First Market Entry
Controlled Introduction → Approval → Commercial Scale
Regulatory Classification & Pathway Confirmation
Formal engagement with national authorities and written confirmation of product classification
1
Controlled Professional Use
Approved settings
and physician-led implementation with safety monitoring and documented outcomes
2
Expanded Authorization / Registration
Registration file built from existing evidence and limited local experience, enabling broader institutional access
3
Controlled Commercialization
Commercial activity only after approved labeling, import permissions, and quality-controlled supply chain activation
4
Clinical Trial Execution
If a clinical trial is mandated by the regulator, MPR BIO will accommodate and execute:
✓ Protocol design and medical writing
✓ Ethics submissions and site activation
✓ Investigator engagement and monitoring
✓ Data collection and safety oversight
Trial scope is aligned to regulator expectations (pilot / pivotal depending on requirement).
Geographical Coverage & Contact Information
Connect with our regional teams to discuss your biopharmaceutical development, manufacturing, or commercialization needs.
North America
Türkiye
Central & Eastern Europe
Middle East & North Africa